Please assess the completion status of the following clinical trial:

Trial Title: Haemocomplettan® P During Aortic Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eighteen years of age or older~* Undergoing elective thoracoabdominal aortic replacement surgery (TAAA) or thoracic aortic replacement surgery (TAA)~* Understood and willingly given written informed consent (German language) to participate following an explanation of study background, restrictions, and procedures~* Experience clinically relevant bleeding of the microvasculature following removal of CPB during surgery~Exclusion Criteria:~* Positive pregnancy test, pregnancy or lactation~* Women of child bearing age not using a medically approved method of contraception during the study~* Previous aortic replacement at the same aortic site (redo surgeries)~* Undergoing an emergency operation~* Proof or suspicion of a congenital or acquired coagulation disorder (e.g. VWD or via severe liver disease)~* Myocardial Infarction (MI) or apoplexy in the 2 months preceding study surgery~* ASA administration in the 3 days preceding study surgery, and a pathological (\<74.5 U) ASPI Multiplate® test immediately preceding surgery begin~* Clopidogrel administration in the 5 days preceding study surgery, and a pathological (\<31.1 U) ADP/PG Multiplate® test immediately preceding surgery begin~* Tirofiban administration in the 2 days preceding study surgery, and a pathological (\<94.1 U) TRAP Multiplate® test immediately preceding surgery begin~* Phenprocoumon administration in the 5 days preceding study surgery, and an INR \> 1.28 immediately preceding surgery begin~* Participation in another clinical study in the 4 weeks preceding aortic replacement~* Sensitivity to any of the components of study medication, or to MPs with a similar chemical structure to any of the components of study medication~* Any indication that the restrictions or procedures of the study may not be adhered to (e.g. an uncooperative attitude)~* Any indication that the study restrictions, procedures, or consequences therein have not been considered or understood, such that informed consent cannot be convincingly given~* Multiple morbidities, with a notably constrained remaining length of life

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haemocomplettan® P (Type: ACTIVE_COMPARATOR): Intravenous infusion during aortic surgery
- Saline solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).